Institute of Pathology, University of Bern, Bern 3008, Switzerland.
Graduate School for Cellular and Biomedical Sciences, Bern 3012, Switzerland.
Oxid Med Cell Longev. 2020 Sep 21;2020:8506572. doi: 10.1155/2020/8506572. eCollection 2020.
LAMP2A and HSC70 are crucial players in chaperone-mediated autophagy (CMA), a targeted, lysosome-dependent protein degradation pathway. Elevated LAMP2A levels, indicative of increased CMA activity, are observed in several malignancies, and CMA downregulation may be exploited therapeutically. We evaluated the impact of LAMP2A and HSC70 in pulmonary squamous cell carcinomas (pSQCC). Antibodies were validated by knockdown and overexpression experiments using three different cell lines. Expression levels in tissue were analyzed by immunohistochemistry in a cohort of 336 consecutive pSQCC using tissue microarrays. There was no significant correlation between the two markers among each other and no association with pathological parameters (TNM categories, grading). However, both high LAMP2A and HSC70 expression were associated with worse outcome, including overall survival (OS; = 0.012 and = 0.001) and disease free survival (DFS; = 0.049 and = 0.036). In multivariate analysis, both markers and a combination of them were independent adverse prognostic factors for OS (LAMP2Ahigh: HR = 2.059; < 0.001; HSC70high: HR = 1.987; < 0.001; LAMP2Ahigh/HSC70high: HR = 1.529; < 0.001) and DFS (LAMP2Ahigh: HR = 1.709; = 0.004; HSC70high: HR = 1.484; = 0.027; LAMP2Ahigh/HSC70high: HR = 1.342, < 0.001). The negative prognostic impact of high LAMP2A and HSC70 and their variable expression in pSQCC may justify the use of these proteins as potential biomarkers for future CMA-inhibiting therapies.
LAMP2A 和 HSC70 是伴侣介导的自噬(CMA)的关键蛋白,CMA 是一种靶向溶酶体的蛋白降解途径。在几种恶性肿瘤中观察到 LAMP2A 水平升高,表明 CMA 活性增加,而 CMA 下调可能具有治疗潜力。我们评估了 LAMP2A 和 HSC70 在肺鳞癌(pSQCC)中的作用。使用三种不同的细胞系通过敲低和过表达实验验证了抗体的特异性。使用组织微阵列对 336 例连续的 pSQCC 组织进行免疫组织化学分析,以检测组织中的表达水平。两种标志物之间没有显著相关性,与病理参数(TNM 分期、分级)也没有关联。然而,LAMP2A 和 HSC70 的高表达均与较差的预后相关,包括总生存(OS; = 0.012 和 = 0.001)和无病生存(DFS; = 0.049 和 = 0.036)。多变量分析显示,两种标志物及其组合均是 OS(LAMP2Ahigh:HR = 2.059; < 0.001;HSC70high:HR = 1.987; < 0.001;LAMP2Ahigh/HSC70high:HR = 1.529; < 0.001)和 DFS(LAMP2Ahigh:HR = 1.709; = 0.004;HSC70high:HR = 1.484; = 0.027;LAMP2Ahigh/HSC70high:HR = 1.342, < 0.001)的不良预后因素。pSQCC 中 LAMP2A 和 HSC70 表达升高及其可变表达的负预后影响可能证明这些蛋白可用作未来 CMA 抑制治疗的潜在生物标志物。